0000000000807108

AUTHOR

Andre Jefremow

showing 2 related works from this author

VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer.

2010

Inflammation drives expression of VEGFR2, which is expressed on and drives growth of tumor cells in colitis-associated cancer.

Vascular Endothelial Growth Factor AColorectal cancerGene Expressionmedicine.disease_causechemistry.chemical_compoundMice0302 clinical medicineImmunology and AllergyDecoy receptorsCells CulturedMice Knockout0303 health sciencesMicroscopy ConfocalReverse Transcriptase Polymerase Chain ReactionDextran Sulfaterespiratory systemColitisImmunohistochemistry3. Good healthUp-RegulationVascular endothelial growth factorVascular endothelial growth factor A030220 oncology & carcinogenesisColonic Neoplasmscardiovascular systemcirculatory and respiratory physiologySignal TransductionSTAT3 Transcription FactorImmunologyBlotting WesternMice TransgenicBiologyArticle03 medical and health sciencesmedicineAnimalsHumans030304 developmental biologyCell ProliferationVascular Endothelial Growth Factor Receptor-1CancerEndothelial CellsKinase insert domain receptorEpithelial CellsCell Biologymedicine.diseaseInflammatory Bowel DiseasesVascular Endothelial Growth Factor Receptor-2Mice Inbred C57BLHIF1AchemistryCancer researchCarcinogenesis030215 immunologyThe Journal of experimental medicine
researchProduct

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

2021

<b><i>Introduction:</i></b> In the REFLECT trial, lenvatinib was found to be noninferior compared to sorafenib in terms of overall survival. Here, we analyze the effects of lenvatinib in the real-life experience of several centers across the world and identify clinical factors that could be significantly associated with survival outcomes. <b><i>Methods:</i></b> The study population was derived from retrospectively collected data of HCC patients treated with lenvatinib. The overall cohort included western and eastern populations from 23 center in five countries. <b><i>Results:</i></b> We included 1,325 patients with HCC …

Second lineSettore MED/12 - GastroenterologiaOncologyHepatologyHepatocellular carcinomaLenvatinibNonalcoholic fatty liver diseaseTyrosine kinase inhibitors.ALBINonalcoholic steatohepatitiNeutrophils to lymphocyte ratioOutcome
researchProduct